SCHEMBL24373790

SCHEMBL24373790

FC1(F)CNCC12CNC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23993480 0.87
Hydrochloric Acid SCHEMBL30224403 0.84
SCHEMBL30224738 0.82
SCHEMBL2068386 0.81
Hydrochloric Acid SCHEMBL31400371 0.80
SCHEMBL24387898 0.80
Hydrochloric Acid SCHEMBL31400329 0.80
SCHEMBL18894340 0.79
Hydrochloric Acid SCHEMBL519207 0.77
Hydrochloric Acid SCHEMBL18865027 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119684305-B Preparation method of 8, 8-difluoro-2, 6-diazaspiro [3.4] octane compound 上海药坦药物研究开发有限公司 2025-11-28 CN disclosed
CN-119684305-B Preparation method of 8, 8-difluoro-2, 6-diazaspiro [3.4] octane compound 上海药坦药物研究开发有限公司 2025-11-28 CN disclosed
CN-119684305-A Preparation method of 8, 8-difluoro-2, 6-diazaspiro [3.4] octane compound 上海药坦药物研究开发有限公司 2025-03-25 CN disclosed
CN-119684305-A Preparation method of 8, 8-difluoro-2, 6-diazaspiro [3.4] octane compound 上海药坦药物研究开发有限公司 2025-03-25 CN disclosed
CN-119684305-A Preparation method of 8, 8-difluoro-2, 6-diazaspiro [3.4] octane compound 上海药坦药物研究开发有限公司 2025-03-25 CN disclosed
WO-2024020419-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2024-01-25 WO disclosed
WO-2022093856-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-05-05 WO disclosed
WO-2022083569-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-04-28 WO disclosed